Drug intelligence / Profile preview

SPK005

Development stage: Preclinical
Lead developer: SpikImm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SPK005 is a monoclonal antibody currently in preclinical development by SpikImm for the prevention and treatment of Human Cytomegalovirus (HCMV) infections. The drug is specifically designed to address the needs of immunocompromised patients, such as solid organ and hematopoietic stem cell transplant recipients, who are at significant risk of morbidity due to CMV reactivation or primary infection. SPK005 was developed using technology from the Institut Pasteur and is part of a pipeline focused on providing passive immunotherapy against opportunistic viral pathogens. The antibody functions by neutralizing the virus, thereby preventing its entry into host cells and limiting viral spread.

Other names: Spik005Spik-005Spik 005

Beyond the preview

Go deeper on SPK005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPK005.

Explore the full profile